Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues

B Wulkersdorfer; T Wanek; M Bauer; M Zeitlinger; M Müller; O Langer

doi:10.1038/clpt.2014.70

Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues

Clin Pharmacol Ther. 2014 Aug;96(2):206-13. doi: 10.1038/clpt.2014.70. Epub 2014 Mar 28.

Authors

B Wulkersdorfer¹, T Wanek², M Bauer¹, M Zeitlinger¹, M Müller¹, O Langer³

Affiliations

¹ Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
² Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
³ 1] Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria [2] Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.

Abstract

Drug disposition is highly regulated by membrane transporters. Some transporter-mediated drug-drug interactions (DDIs) may not manifest themselves in changes in systemic exposure but rather in changes in tissue exposure of drugs. To better assess the impact of transporter-mediated DDIs in tissues, positron emission tomography (PET)-a noninvasive imaging method--plays an increasingly important role. In this article, we provide examples of how PET can be used to assess transporter-mediated DDIs in different organs.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Drug Interactions / physiology*
Humans
Membrane Transport Proteins / metabolism*
Pharmaceutical Preparations / metabolism*
Positron-Emission Tomography / methods
Positron-Emission Tomography / statistics & numerical data*
Tissue Distribution / drug effects
Tissue Distribution / physiology

Substances

Membrane Transport Proteins
Pharmaceutical Preparations